Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Stopped Repros stopped the study for safety and FDA put the study on hold for safety.

Conditions

• Uterine Fibroids

Interventions

• DRUG: Proellex 25 mg
• DRUG: Proellex 50 mg
• DRUG: Lupron Depot

Sponsor

Repros Therapeutics Inc.